SCM
NWBO

Stevens Capital Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Stevens Capital Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-16,623
Closed -$165K – 1445
2015
Q2 		$165K Buy
+16,623
New +$146K 0.01% 905
2014
Q4 		– Sell
-35,512
Closed -$179K – 1436
2014
Q3 		$179K Buy
+35,512
New +$218K 0.01% 878

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stevens Capital Management's NWBO Position: Q3 2015 in Review

Stevens Capital Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2015, closing a stake of 16,623 shares — an estimated $165K sold.

Stevens Capital Management first reported a position in NWBO in Q3 2014 and held it in 2 quarters. The position peaked at $179K in Q3 2014. 79 funds tracked by Wall St. Rank hold NWBO as of Q3 2015.

  • Stevens Capital Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2015 after selling out during the quarter.
  • Stevens Capital Management sold 16,623 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2015, an estimated $165K.
  • Stevens Capital Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2014 and held it in 2 quarters.
  • Stevens Capital Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $179K in Q3 2014.
  • 79 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2015.

Based on Stevens Capital Management's 13F filing for Q3 2015, filed 10 Nov 2015.